康臣药业集团有限公司（股票代码：01681）于2026年8月4日发布截至2026年7月31日的月度证券变动报告。公告显示，公司的法定股本及注册股本继续维持在5,000,000,000股（每股面值0.1港元），合计约5亿港元，与上月保持一致。
截至2026年7月底，康臣药业已发行股份数量为839,049,111股，库存股份数量为2,498,000股，总发行股本数为841,547,111股，亦与上月持平。报告期内未发生任何新增发行、购回或注销，不影响公司现有股本结构的稳定性。
关于股权激励计划，2013年12月2日采纳的购股权计划在本月内从上月底结存的7,074,153份期权变动至期末为0份；2024年5月31日采纳的购股权计划本月无新增期权与变动，截至期末可行使或转让的数量为84,281,191股。公司同时声明严格遵守香港联合交易所有限公司证券上市规则及相关法律法规。本次公告由公司秘书高海恩签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.